Abstract
Cardiac amyloidosis, thought to be rare, is increasingly recognized and benefits from newer therapeutic options. This article provides a practical approach for the clinical cardiologist to the non-invasive assessment of cardiac amyloidosis, from clinical red flags to the appropriate use of echocardiography, cardiovascular magnetic resonance imaging, and technetium-99m pyrophosphate scintigraphy in the screening, diagnosis, and prognosis of cardiac amyloidosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
